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Highlights 
 Traditional efficacy double-blind randomised controlled trials (DBRCTs) are considered 
the “gold standard” study design for assessing the efficacy and safety of new medicines; 
however, their conduct in highly selected patient populations and in highly controlled, 
artificial/constrained settings limits the generalisability of their findings to patients seen 
in everyday clinical practice. 
 Pragmatic effectiveness trials conducted in the routine clinical care setting allow for the 
evaluation of the effectiveness of medicines in the presence of real-world factors related 
to patients, actual medication use, and healthcare systems, thus providing a more 
complete picture of the benefit/risk profile of a medicine to support healthcare decision-
making. 
 In this article, we discuss the key features and advantages/limitations of pragmatic 
effectiveness randomised controlled trials (RCTs) compared with traditional efficacy 
DBRCTs, using the Salford Lung Study (SLS) programme as an illustrative example. 
 SLS was the world’s first prospective, Phase III, pragmatic RCT to evaluate the 
effectiveness of a pre-licensed medication in a primary care setting using electronic 
health records and through collaboratively engaging general practitioners and 
community pharmacists in clinical research. 
 Key learnings from SLS that may help inform the design of future pragmatic 
effectiveness RCTs include: (1) ensuring that the trial setting and operational 
infrastructure are aligned with routine clinical care; (2) recruiting a broad population of 
patients with characteristics as close as possible to patients seen in routine clinical 
practice, to maximise the generalisability and applicability of the trial results; (3) 
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ensuring that patients and local healthcare professionals are suitably engaged in the 
trial, to maximise the chances of successful trial delivery; and (4) careful study design, 
incorporating outcomes of value to patients, healthcare professionals, policymakers and 
payers, and using pre-planned analyses to address scientifically valid research 
hypotheses to ensure robustness of the acquired data. 
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Abstract 
Traditional efficacy double-blind randomised controlled trials (DBRCTs) measure the benefit 
a treatment produces under near-ideal test conditions in highly selected patient 
populations; however, the behaviour of patients and investigators in such trials is highly 
controlled, highly compliant and adherent, and non-representative of routine clinical 
practice. Pragmatic effectiveness trials measure the benefit a treatment produces in 
patients in everyday “real-world” practice. Ideally, effectiveness trials should recruit 
patients as similar as possible to those who will ultimately be prescribed the medicine, and 
create freedom within the study design to allow normal behaviours of patients and 
healthcare professionals (HCPs) to be expressed. The Salford Lung Study (SLS) was a world-
first, prospective, Phase III, pragmatic randomised controlled trial (RCT) programme in 
patients with chronic obstructive pulmonary disease and asthma to evaluate the 
effectiveness of a pre-licensed medication (fluticasone furoate/vilanterol) in real-world 
practice using electronic health records and through collaboratively engaging general 
practitioners and community pharmacists in clinical research. The real-world aspect of SLS 
was unique, requiring careful planning and attention to the goals of maximising the external 
validity of the trials while maintaining scientific rigour and securing suitable electronic 
processes for proper interpretation of safety data. Key learnings from SLS that may inform 
the design of future pragmatic effectiveness RCTs include: (1) ensuring the trial setting and 
operational infrastructure are aligned with routine clinical care; (2) recruiting a broad 
patient population with characteristics as close as possible to patients in routine clinical 
practice, to maximise the generalisability and applicability of trial results; (3) ensuring that 
patients and HCPs are suitably engaged in the trial, to maximise the chances of successful 
trial delivery; and (4) careful study design, incorporating outcomes of value to patients, 
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HCPs, policymakers and payers, and using pre-planned analyses to address scientifically 
valid research hypotheses to ensure robustness of the trial data. 
Keywords: Salford Lung Study; Asthma; Chronic obstructive pulmonary disease; Randomised 
controlled trial; Effectiveness; Fluticasone furoate/vilanterol; Primary care; Real world; 
Usual care  
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Introduction 
Double-blind randomised controlled trials (DBRCTs) are considered the “gold standard” 
study design for assessing the efficacy and safety of new medicines, and are designed to 
achieve maximum internal validity with minimal potential for confounding factors [1]. 
Frequently conducted for the purpose of obtaining data to support regulatory approvals, 
DBRCTs underpin the evidence base informing treatment guidelines and healthcare 
decisions [1–3]. However, as efficacy DBRCTs are conducted in highly selected patient 
populations and under highly controlled, “artificial” conditions (Fig. 1) optimised to 
demonstrate the effect of the medicine, the generalisability of their findings to the overall 
disease population may be limited [3–7].  
Pragmatic randomised effectiveness trials are designed to evaluate medicines in the 
“real-world” setting across a broad patient population [8, 9] (Fig. 1) and offer the 
opportunity to address issues faced by patients and healthcare professionals (HCPs) on a 
daily basis [3, 6], while retaining the benefits of random treatment allocation. Randomised 
effectiveness trials can complement traditional efficacy DBRCTs by filling the evidence gaps 
surrounding patient and physician experience, treatment adherence, and healthcare 
resource utilisation (HRU) and care costs, all of which are key to informing healthcare 
decision-making [9]. 
The Phase IIIb, pragmatic effectiveness Salford Lung Study (SLS) RCT programme was 
designed to evaluate a pre-licensed inhaled corticosteroid/long-acting β2-agonist 
combination, fluticasone furoate/vilanterol (FF/VI), in patients with chronic obstructive 
pulmonary disease (COPD) and asthma in UK primary care [10]. SLS was a world-first, 
embracing the novel use of electronic health records (EHRs) to comprehensively enrol a 
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broad spectrum of patients from across Salford and surrounding areas. Here, we discuss key 
features and advantages/limitations of pragmatic effectiveness RCTs versus traditional 
efficacy DBRCTs (focusing on respiratory trials), using SLS as an illustrative example. We also 
describe key learnings from SLS and discuss how these might help inform the design of 
future pragmatic effectiveness RCTs and respiratory treatment guidelines/healthcare 
policies. 
Efficacy and Effectiveness RCTs: Overview and Major Differences 
The behaviour of patients and HCPs in traditional efficacy DBRCTs is highly controlled, highly 
compliant and adherent, and non-representative of routine clinical practice [1, 3, 6]. 
Effectiveness trials measure the benefit a treatment produces in patients in everyday, real-
world practice [1]. Ideally, effectiveness trials should recruit patients as similar as possible to 
those to whom the medicine will eventually be prescribed and create freedom within the 
study design to allow normal patient and HCP behaviours to be expressed. 
Table 1 compares features of traditional efficacy DBRCTs versus pragmatic effectiveness 
RCTs. Efficacy DBRCTs are generally conducted in hospitals/specialised research centres and 
assess highly selected patient populations. Pragmatic effectiveness RCTs are set in routine 
care, are typically open-label (i.e., patients and HCPs have knowledge of assigned 
treatment), and are inclusive of patients with coexisting medical conditions and diverse 
symptoms. The protocols of efficacy DBRCTs demand atypical conduct from both patients 
and HCPs, often requiring frequent, rigorous, and prolonged assessments by trial 
investigators/dedicated study team, and restricting freedom of choice (e.g., a decision to 
add another medication is often labelled a “protocol violation” without understanding the 
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underlying reason). Effectiveness trials typically mandate few study visits, to mimic real-
world practice and preserve usual behaviours as closely as possible. 
The strict inclusion/exclusion criteria of traditional efficacy DBRCTs are designed to 
maximise internal validity and reduce the impact of biases. However, in the real-world 
setting, patients with COPD and asthma arrive at the doctor’s office with many 
confounding/complicating factors not assessed in DBRCTs, which can have profound effects 
on the likelihood of a medicine causing benefit or harm (Box 1).  
Box 1 Examples of patient confounding/complicating factors in the real-world clinical practice 
settinga 
 Existing diagnosis (often pragmatic or clinical) 
 Access to medical care 
 Non-adherence to prescribed medication (over- or under-treating) 
 Poor inhaler techniqueb 
 Poor compliance with treatment advice and follow-up 
 Comorbidities/coexisting medical conditions 
 Polypharmacy 
 Cigarette smoking and/or recreational drug use 
 Variability in health literacy 
 Diversions and distractions caused by life and social events, crises, shift-work patterns, 
accidents and injuries 
a Many of these factors preclude patients from being eligible, or wanting, to participate in 
traditional highly controlled DBRCTs 
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 b Specific to the respiratory setting 
 
Almost all of these factors are excluded/altered by the strict eligibility criteria, conduct, and 
need for protocol compliance in traditional efficacy DBRCTs. Consequently, only a low 
proportion of primary care patients with COPD and asthma would be eligible for 
participation in typical efficacy trials [4, 11–14] and the relevance of DBRCT results to 
patients in routine practice is limited [1, 7]. Effectiveness RCTs can therefore supplement 
data from efficacy DBRCTs by providing a more complete picture of the benefit/risk profile 
of a medicine to support healthcare decision-making. 
The inherent design differences between traditional efficacy DBRCTs and pragmatic 
effectiveness RCTs result in different strengths and limitations of the acquired data (Box 2).  
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Box 2 Traditional efficacy DBRCTs versus pragmatic effectiveness RCTs: impact of study design aspects on acquired data 
 Scenario Pros Cons 
Process of care 
 
In DBRCTs: 
 Protocols demand atypical conduct 
from patients and HCPs, often 
requiring frequent, rigorous and 
prolonged study assessments 
 Optimal treatment compliance and 
inhaler device technique is strongly 
encouraged 
 Treatment pathway is strictly 
defined, and deviations from 
prespecified treatment may result in 
patients being withdrawn from study 
(restricting freedom of choice 
around patient care). 
 
 Rigorous assessment in efficacy 
DBRCTs allows for robust data 
acquisition and for patient safety to 
be closely monitored. 
 By strongly encouraging optimal 
treatment compliance, DBRCTs are 
able to provide an accurate profile of 
treatment efficacy and safety for an 
intended dose. 
 
 A downside of the “artificial”highly 
controlled environment in which 
efficacy DBRCTs are conducted is the 
impact on the behaviour of both 
patients and physicians, which does not 
truly reflect the characteristics of a 
medicine when used in the real-world 
setting. 
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 In pragmatic effectiveness RCTs: 
 Care is aligned with that received in 
routine clinical practice, with 
minimal scheduled study 
visits/assessments and minimal 
disruption to patients’ everyday lives 
 Physicians have freedom of choice to 
modify patients’ treatment as 
deemed necessary. 
 
 Study design permits freedom of 
choice around patients’ care and 
allows the normal behaviours of 
patients and HCPs to be expressed; 
thus, acquired data may be more 
generalisable to patients seen in 
everyday clinical practice. 
 
 Data from pragmatic effectiveness trials 
more likely to be confounded by 
extraneous variables, not controlled for 
by virtue of the trial being conducted in 
a real-world setting. 
Data collection   In efficacy DBRCTs, patients’ data are 
typically entered into eCRFs by 
investigators/dedicated study team 
members during or following 
scheduled study visits.  
 The challenge for pragmatic 
effectiveness trial design is to 
 Compared with eCRFs, EHR-based 
data capture has advantages in terms 
of allowing for remote data collection 
in real time (avoiding recall or 
transcription bias) and in providing 
the opportunity for long-term follow-
 Disadvantages of EHR-based data 
capture include missing data, lack of 
representation of endpoints of interest, 
and potential issues with accessibility 
for research purposes in certain 
regions/countries. 
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adequately balance the delivery of 
highly accurate and complete data 
with minimising the level of 
interference that data entry and 
verification pose to routine practice. 
Effectiveness trials may rely on data 
extraction from patients’ EHRs or 
other spontaneous reporting 
systems, as well as eCRFs for data 
capture. 
 In contrast to traditional efficacy 
DBRCTs, where neither investigator 
nor patient has knowledge of the 
assigned treatment, pragmatic 
effectiveness RCTs are typically 
open-label in design. 
up of the trial population after the 
study has completed. 
 Conducting effectiveness trials in 
routine clinical care means that some 
investigators may be inexperienced in 
clinical research and processes must be 
implemented to manage this to ensure 
robust data collection (accordingly with 
resource, logistics, and cost 
implications).  
 An open-label study design creates the 
potential for bias in the acquired data 
due to behavioural effects that arise as 
a consequence of knowledge of the 
treatment that has been administered, 
e.g.,:  
o Physicians may be biased in assigning 
causality of AEs to an investigational 
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medicine rather than to a well-
established standard-of-care 
treatment where common AEs are 
well known – this could have a 
positive or negative effect on AE 
reporting 
o There may be increased HCP/patient 
vigilance with a new medicine, 
resulting in higher rates of healthcare 
contacts than with a more familiar 
treatment option 
o Patients may merely have a 
preference for, and revert to taking, a 
more familiar treatment, thus 
impacting on adherence to the 
assigned study treatment. 
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 The Hawthorne effect—where 
individuals modify an aspect of their 
behaviour in response to their 
awareness of being observed—may 
apply and confound data collected in 
both traditional efficacy DBRCTs and 
pragmatic effectiveness RCTs; however, 
this effect may be less likely in 
effectiveness trials that are designed to 
minimise disruption to everyday clinical 
care.  
Trial eligibility 
criteria / 
patient 
population 
 The stringency of eligibility criteria 
for traditional efficacy DBRCTs 
versus pragmatic effectiveness RCTs 
will dictate the nature of the patient 
populations recruited, and this can 
 The highly selected patient 
populations in traditional efficacy 
DBRCTs allow for testing of the 
efficacy of a medicine under 
conditions where confounding factors 
 The strict entry criteria/requirements 
for adherence to protocol in traditional 
efficacy DBRCTs may preclude 
otherwise eligible patients from 
participating (e.g., patients from 
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have a profound effect on the data 
collected during such trials.  
 Patients in traditional efficacy 
DBRCTs are usually recruited in 
hospitals/specialised 
researchambulatory care/outpatient 
centres, tend to be healthier than 
the non-trial disease population, and 
often participate in multiple trials. 
 In high-recruiting research centres, 
investigators may hold a database of 
patients who are “ready to enrol”. 
Such patients will meet trial 
inclusion/exclusion criteria as 
standard, are quick to learn and 
maintain excellent inhaler technique, 
are minimised; thus, data have high 
internal validity.  
  
deprived areas, for reasons including 
difficulties with/costs of getting to the 
research site, or working and family 
commitments). This has led to the 
concept of “persistent participators” in 
efficacy DBRCTs—a population that is 
non-representative of patients treated 
in real-world practice.  
 Findings from efficacy DBRCTs have 
limited applicability/generalisability of 
the acquired data to the wider disease 
population—low external validity. 
o An example would be the collection 
and interpretation of AEs. In a 
pragmatic effectiveness trial, by 
virtue of enrolling a broader 
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intellectually capable, highly 
compliant with study protocols and 
procedures, and are familiar with a 
range of treatment devices and 
study assessments.  
 Pragmatic effectiveness RCTs seek to 
recruit a broad participant 
population with characteristics as 
similar as possible to patients who 
will eventually be prescribed the 
medicine in routine clinical practice. 
To achieve this, such trials typically 
employ minimal inclusion/exclusion 
criteria. 
population of patients (including 
those with comorbidities and more 
severe disease), it is likely that a 
higher incidence and/or wider variety 
of AEs will be reported than in an 
efficacy DBRCT evaluating the same 
medicine. 
 These limitations are somewhat 
circumvented in pragmatic 
effectiveness RCTs. 
 In pragmatic effectiveness RCTs, 
recruiting a broad participant 
population may introduce additional 
variability to the dataset, and a greater 
number of patients may need to be 
enrolled to power the study to 
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demonstrate treatment effect, 
compared with traditional efficacy RCTs. 
Outcomes  Endpoints in traditional efficacy 
DBRCTs (registrational trials in 
particular) are often dictated by 
outcomes of interest to regulatory 
authorities, often require frequent 
assessments and diary 
cards/electronic diaries, and serve as 
constant reminders of disease state 
and treatment response. 
 In pragmatic effectiveness RCTs, it is 
desirable to select endpoints that 
are relevant to patient-centric goals 
for treatment and that physicians 
routinely use to assess patients and 
 In effectiveness trials, it is desirable 
to minimise the impact of study 
assessments by selecting endpoints 
and a frequency of measures that 
ideally can be gathered with little or 
no impact on the patient or HCP, and 
where observer bias is controlled—
crucial for an open-label study 
design.  
 In pragmatic effectiveness RCTs, certain 
endpoints may be precluded due to the 
intensive monitoring that would be 
required (e.g., serial lung function, daily 
diaries). 
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make treatment decisions, so as to 
optimise external validity and 
transferability of the data, and 
enhance value to clinicians, payers, 
and policymakers. 
o In respiratory trials, for example, 
such endpoints would include 
exacerbations, hospitalisations, 
mortality, validated patient-
reported outcomes, and quality-
of-life measures.  
Data analysis / 
interpretation 
 In routine clinical practice, a 
patient’s treatment will be adjusted 
at the discretion of the treating 
physician.  
 In traditional DBRCTs, efficacy and 
safety endpoints are typically 
analysed according to the ITT 
principle. Interpretation of data is 
more straightforward; randomisation 
 In effectiveness RCTs, variation in the 
treatment being taken produces an 
additional level of complexity for data 
analysis, in that it precludes the direct 
comparison of randomisation groups 
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 Treatment modifications are rarely 
permitted in traditional efficacy 
DBRCTs, but are allowed (albeit with 
potential restrictions) in pragmatic 
effectiveness RCTs, with implications 
for the analysis and interpretation of 
the study data (particularly 
important for safety evaluation). 
 In effectiveness RCTs where 
treatment can be modified, careful 
consideration must be taken as to 
whether specific study endpoints will 
be evaluated as ITT (i.e., according to 
randomised treatment group) or by 
actual treatment received. 
group equates to treatment group 
and data can be analysed accordingly 
(e.g., safety events can be attributed 
to randomised treatment). 
 In effectiveness RCTs, analysis by 
actual treatment received allows for 
assessment of true exposure risk of a 
medication. 
from being equated with the safety of 
treatment A compared with treatment 
B. 
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o Effectiveness endpoints will 
typically be analysed as ITT, which 
is equivalent to comparing the 
treatment strategies being 
investigated in the effectiveness 
RCT. 
o Safety data ought to be presented 
both by randomised treatment 
group and also by actual 
treatment. 
AE adverse event, DBRCT double-blind randomised controlled trial, eCRF electronic case report form, EHR electronic health record, HCP 
healthcare professional, ITT intent to treat, RCT randomised controlled trial 
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The Salford Lung Studies in COPD and Asthma: What Were Their Novel "Real-
World" Aspects? 
The SLS programme comprised two concurrent, 12-month, open-label, Phase IIIb 
pragmatic RCTs designed to evaluate the effectiveness and safety of initiating once-daily 
inhaled FF/VI, compared with continuing usual care (UC) in patients with COPD or asthma in 
UK primary care [10, 15–18]. All patients provided written informed consent for 
participation in SLS and the trials were conducted in accordance with the International 
Conference on Harmonisation Good Clinical Practice guidelines and the provisions of the 
2008 Declaration of Helsinki. The trial protocols were approved by the National Research 
Ethics Service Committee North West, Greater Manchester South (approval numbers 
11/NW/0798 and 12/NW/0455).   
When SLS commenced, a full regulatory submission for FF/VI was under consideration 
by the European Medicines Agency based on extensive efficacy and safety data from 
completed RCTs [10]. SLS was conducted to meet the need for effectiveness data for FF/VI 
to complement existing evidence from efficacy RCTs. SLS was the first study in the UK to 
take advantage of joint advice from the Medicines and Healthcare products Regulatory 
Agency (MHRA) and The National Institute for Health and Care Excellence (NICE). MHRA, 
responding positively to NICE’s enthusiasm for pragmatic data in a broad community, 
approved the study design with a pre-licensed medicine — ; this confident decision was a 
key factor in enabling the study to proceed. 
SLS innovatively evaluated the effectiveness of a pre-licensed medication in the real-
world setting using EHRs [10, 19] and collaboratively engaged general practitioners (GPs) 
and community pharmacists in clinical research. The SLS trial designs have been reported 
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previously [10, 15–18] (Fig. 2). The studies employed broad eligibility criteria to recruit large, 
heterogeneous populations of patients with COPD and asthma. There were few protocol-
mandated clinic visits and data were collected continuously and remotely from patients’ 
EHRs using a primary/secondary care-linked database system (as well as via electronic case 
report forms [eCRFs]). Patients were recruited and managed by their usual GPs, who 
prescribed as normal, and patients ordered and collected repeat prescriptions in the usual 
way and collected their study medication from their usual community pharmacist. 
Treatment modifications were permitted at GPs’ discretion during the study; patients 
randomised to initiate FF/VI could modify their treatment to any other appropriate 
treatment and remain in the FF/VI randomisation group. Those randomised to continue UC 
were also allowed to modify their treatment to any other appropriate treatment (except for 
FF/VI) and remain in the UC randomisation group. The real-world design aspect of SLS was 
unique, requiring careful planning and attention to the goals of maximising the external 
validity of the trials while maintaining scientific rigour, as well as securing suitable electronic 
processes for proper interpretation of safety data.  
Maximising External Validity 
Careful design and much background work went into ensuring that the delivery of SLS was 
aligned with routine care (e.g., normality of medicines supply; patient and HCP behaviours 
consistent with everyday clinical practice; interplay between patients, GPs, pharmacists in 
the community setting), while ensuring that the study conduct and data collection met the 
requirements of a Phase IIIb RCT.  
Collecting patients’ data via EHRs allowed us to measure the SLS COPD primary 
effectiveness endpoint (moderate/severe exacerbations) through surrogates triggered in 
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the EHR (prescription of antibiotics and/or systemic corticosteroids or hospital 
admissions/visits associated with a respiratory cause [17]). This ensured that patients and 
doctors were essentially unaffected by the study for the entire follow-up period. In SLS 
asthma, the same primary effectiveness endpoint was not feasible due to the expected low 
frequency of exacerbations based on a pilot study (recruitment numbers would have been 
too high to achieve the required statistical power); instead, response on Asthma Control 
Test (ACT) was selected as the primary outcome. ACT was completed by patients at the 
baseline (randomisation) and Week 52 (end of study) scheduled visits, and was additionally 
administered via telephone at Weeks 12, 24, and 40 [18]. Processes were implemented to 
ensure that ACT was administered with minimal interference to normal care (e.g., GPs were 
aware of ACT scores at baseline, but not thereafter; telephone ACT was administered by a 
study nurse blinded to treatment and who was trained not to provide advice to the patient, 
except under life-threatening circumstances).  
All HCPs involved in SLS (GPs, nurses, pharmacists, and their staff) were trained to 
allow routine clinical practice to proceed, although consultation rates were higher in the 
FF/VI randomisation group than the UC group during the first 12 weeks [20, 21], 
predominantly for non-respiratory reasons, suggesting that GPs and patients did undergo an 
initial familiarisation period with the new therapy. Importantly, by extracting HRU data 
directly from EHRs, we were able to obtain a complete picture of the burden associated 
with COPD and asthma without bias due to recall or transcription of data, and were able to 
demonstrate a disproportionately high resource use for non-COPD/-asthma reasons [20, 
21]. 
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This “hands-off” approach really allowed normal patient and HCP behaviours to play 
out in SLS—quite unusual for a Phase III trial, and a very positive aspect of the trial design, 
as it provides valuable information about how FF/VI performs when used in routine practice.  
Maintaining Scientific Rigour 
Through its prospective design, baseline randomisation/stratification procedures, and 
extensive a priori analysis plan, SLS achieved the scientific rigour characteristic of a 
traditional efficacy RCT. Much consideration went into the decision to allow asymmetric 
treatment modification in the trial design and the subsequent impact this would have on 
the data analyses (analysis by randomised treatment group or by actual treatment).  
Furthermore, for the purpose of statistics and programming, the sponsor remained 
blinded to study treatment while the trial was ongoing and was only unblinded after all data 
had been collected and the study database had been locked, thus mimicking the approach 
taken in a typical DBRCT. 
Safety Data Collection 
SLS commenced with a pre-licensed medicine and our intention was to vigilantly collect and 
evaluate in real-time safety events through patients’ EHRs. In recruiting a population 
inclusive of patients with comorbidities and severe disease, we anticipated that the study 
would accrue a large volume of safety data and that patients would experience multiple 
serious adverse events (SAEs) that would not be seen in trials where such comorbidities are 
excluded. An innovative approach for identifying potential AEs without interfering with 
patients’ normal routines was essential. The SLS safety data collection process has been 
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published previously [19], but a key aspect of this was the creation of a consultant-led 
specialist safety team, who were alerted to review potential safety events in real time.  
Over 7000 patients participated in SLS and both trials met their primary effectiveness 
endpoints, demonstrating the benefit of initiating FF/VI versus continuing UC [17, 18]. In SLS 
COPD, there was a statistically significant reduction for FF/VI versus UC in the mean annual 
rate of moderate/severe exacerbations, without increased risk of SAEs [17]. In SLS asthma, 
the odds of patients being ACT responders (ACT total score ≥20 and/or improvement from 
baseline ≥3) at Week 24 were significantly higher for FF/VI versus UC, without increased risk 
of SAEs [18]. Consistent benefit of FF/VI over UC has also been demonstrated for various 
other endpoints, as demonstrated in secondary analyses of SLS COPD and asthma [20–29]. 
SLS Approach to Effectiveness RCTs: Advantages and Limitations 
Conducting effectiveness RCTs such as SLS in routine primary care requires access to the 
patient population of interest and good infrastructure, operational management, 
training/good clinical practice, and site engagement. It could be argued that such 
requirements could preclude the conduct of similar effectiveness studies in other 
geographical locations [30].  
As SLS comprised Phase IIIb trials of a pre-licensed medication requiring detailed 
safety monitoring, the studies were time- and resource-intensive to design and the 
operational logistics were highly complex. There exists a perception that effectiveness 
studies are simpler to design and less expensive to implement than traditional efficacy RCTs, 
but our experience with SLS suggests quite the opposite; however, this may not necessarily 
reflect requirements for all real-world effectiveness studies, which should be designed on a 
case-by-case basis. 
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SLS commenced with a phase of pre-licensed FF/VI in the UK primary care setting and 
this had implications for the acquired trial dataset, which should be considered when 
designing similar future effectiveness RCTs. For example, in SLS COPD, higher rates of all-
cause primary care contacts for FF/VI versus UC were observed in the first three months of 
the study, which may have been driven by additional scrutiny of the then-unlicensed FF/VI 
[20]. Patients and physicians were allowed to modify treatment, and this required an 
additional level of consideration around the underlying reasons for modification and had 
implications for data analysis. In SLS, we were able to determine actual HRU and care costs 
(as opposed to the usual modelled costs) for patients with COPD and asthma, which is highly 
relevant for routine clinical practice in the UK. Furthermore, patients from deprived areas, 
who may be ineligible for, or unwilling to participate in, traditional Phase III RCTs were 
recruited to the SLS. Salford, UK, is an urban location with areas of deprivation. Asthma 
patients were equally represented in deprivation categories, but COPD patients are over 
represented in deprived areas. In an analysis of outcomes by deprivation, we found that 
deprivation did not impact the main outcomes of the SLS trials, thus supporting the 
recruitment of participants from all socioeconomic strata to provide data that are 
generalisable to routine clinical practice [26‒28].  
To reflect the routine clinical care setting, the UC randomisation group comprised 
many different inhaled maintenance therapies as the comparator for initiation of FF/VI, 
which could also be varied over the course of the study. Caveats of this design aspect 
include a limited capacity to prospectively evaluate FF/VI against a specific UC treatment, 
and inability to equate a UC option with an established standard-of-care in COPD or asthma. 
Allowing broad UC therapies and treatment modifications in SLS has limitations for data 
analysis (precludes direct, head-to-head comparisons of FF/VI versus UC, or of FF/VI versus 
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one particular UC treatment), but advantages in that analysis by actual treatment could be 
conducted (e.g., safety reporting). 
How Might SLS Inform HCPs and Decision-Makers? 
For most newly approved medicines, evidence from efficacy DBRCTs is insufficient to fully 
guide physicians in choosing optimal treatment for their patients. Pragmatic effectiveness 
trials can fill the gap by providing data on the overall treatment strategy in routine clinical 
practice while maintaining the strength of an RCT [3] and are a valid option for addressing 
issues that patients, clinicians and policymakers face on a daily basis. Knowledge of the 
overall effectiveness of a medicine in the intended patient population, taking into account 
real-world factors related to patients, actual medication use, and healthcare systems, will 
ultimately help HCPs make more-informed treatment choices for their patients. 
Furthermore, this study is the first to provide HCPs with answers on how initiating FF/VI 
(having been treated previously with other medicines) may impact exacerbation rates and 
other outcomes versus continuing on those other medicines. 
In respiratory clinical care, there has tended to be a focus on symptom management; 
however, patients are often more concerned with how their symptoms make them feel and 
the impact of symptoms on their everyday lives [31]. Health care is increasingly adopting a 
patient-centric approach, which considers patients’ perspectives regarding the impact of 
disease and its treatment. Clinical trials should, therefore, incorporate appropriate patient-
reported outcomes (PROs) and quality of life (QoL) outcomes in their design. In SLS asthma, 
several PRO effectiveness endpoints were prospectively assessed (including ACT, Asthma 
Quality of Life Questionnaire, Work Productivity and Impairment Questionnaire: Asthma, 
and the EuroQol 5-Dimensions 3-Levels questionnaire). Initiation of FF/VI was associated 
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with consistent benefits in PROs versus continuing UC, demonstrating that the observed 
improvement in asthma control (measured by ACT) for FF/VI translates into patient-
perceived benefits in health-related QoL [23]. Follow-up interview-based studies conducted 
in subsets of patients who completed SLS have also provided important additional findings 
on patient-centred outcomes relevant to respiratory care in routine clinical practice [24, 32, 
33].  
For healthcare policy decision-makers, data from effectiveness trials can provide a 
more balanced view of the overall benefit/risk of a medicine, including HRU and cost-
effectiveness — critical factors for consideration by resource-limited health services [10]. 
However, despite Health Technology Assessment groups expressing a desire to see more 
pragmatic studies describing effectiveness, for many, their dossier restrictions do not allow 
unblinded studies to be included in their assessments. There have been few studies like SLS 
in Phase III and so payers and regulators have little experience of the nuances of such 
datasets and how to respond to them within their regulation. However, unless they do so, 
this will have a negative impact on sponsors’ willingness to fund effectiveness studies. 
Learnings from SLS: How can These be Applied to Future RCTs? 
Pragmatic real-world study design requires careful consideration of the setting, patient 
population, intervention, comparator, and outcomes [3]. Here, we discuss key learnings 
from SLS and how these might help inform the design of future effectiveness RCTs. 
Considerable effort and time was spent on aspects of the study design and 
operationalisation beyond our experience in DBRCTs; these aspects are summarised in Table 
2. 
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Setting and Infrastructure  
The underlying operational infrastructure was the key to delivering two large Phase IIIb 
trials evaluating a pre-licensed medicine out of local GP practices and pharmacies in and 
around Salford, UK. Salford was an ideal location for the trials due to its relatively static 
population served by a single hospital with an integrated, real-time EHR connection with 
surrounding primary care practices and linking with patient-level prescription information 
(Salford Integrated Record; SIR) [10]. A bespoke information technology infrastructure was 
developed by NorthWest eHealth to extract data from the SIR for the purpose of 
effectiveness research [10, 19]. Over 2100 GPs, nurses, and pharmacy staff in and around 
Salford were trained in good clinical practice in SLS. 
Critical to the successful delivery of SLS was the unique involvement and collaboration 
and absolute commitment of community pharmacies. A key component of the integrity of 
the effectiveness design was maintaining the normality of repeat prescribing and dispensing 
in a situation where a pre-licensed medicine was being evaluated. Extensive training and 
process development permitted pharmacists/pharmacy staff to participate in a Phase III 
trial, despite most having no prior clinical research experience. SLS demonstrated that 
pharmacies normally competing for prescription business can work in a collaborative and 
supportive manner for the benefits of patients. Specific aspects of how pharmacy 
involvement was successfully achieved in the SLS will be the subject of another publication 
[34]. 
Patient Population—Inclusiveness and Applicability 
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SLS showed that by employing limited eligibility criteria, it is possible to recruit to a Phase 
IIIb effectiveness RCT a broad population of patients that are representative of those in 
everyday clinical practice, including from socioeconomically deprived areas.  
SLS COPD enrolled approximately half of all eligible patients with COPD in the target 
geographical area [7]. These patients had a high disease burden and more symptoms, more 
frequent exacerbations, more comorbidities, and more SAEs/pneumonia SAEs compared 
with patients in large, registrational, efficacy RCTs in COPD [7]. Furthermore, over half of SLS 
COPD patients were categorised in the most deprived quintile by postcode [26, 28]. Notably, 
only ≤30% of SLS COPD patients would have been eligible for a typical regulatory Phase III 
COPD exacerbation study [7], definitively demonstrating that COPD patients enrolled in 
traditional efficacy RCTs are not representative of patients in primary care.  
The applicability of SLS findings to patients in routine clinical care is supported by a 
previous study demonstrating similarity in the characteristics of SLS COPD patients with 
other primary care patient populations across Europe [35]. Further support comes from a 
recent observational study demonstrating that patients in the SLS COPD UC group were 
similar to a matched cohort of non-trial COPD patients in England from the Clinical Practice 
Research Datalink database [36]. Evidence for a Hawthorne effect was observed, with a 
higher frequency of COPD exacerbations recorded in SLS patients than in non-trial patients; 
however, the largest effect was observed through behavioural changes in patients and GP 
coding practices [36]. SLS data have, therefore, contributed to the development of novel 
methods for evaluating the presence of an operating Hawthorne effect for future 
effectiveness trials conducted in everyday clinical practice.  
Patient and HCP Engagement  
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Our experience with SLS underscores the importance of carefully designing pragmatic 
effectiveness RCTs to maximise chances of success in routine practice while ensuring 
operational feasibility. Engaging patients and HCPs in effectiveness research is extremely 
challenging. Initially, patient enrolment was slow in the SLS and we had to revisit our 
strategies for recruitment. The key was the involvement of patients’ own GPs in recruitment 
and obtaining of consent. Following on from SLS, additional qualitative research has been 
conducted to understand the drivers for patient and HCP engagement in the studies and 
how participation in future effectiveness trials might be enhanced [37]. Though key 
learnings from SLS will be the subject of a separate publication, our findings should be 
highlighted around the overall positive experience of patients and healthcare professionals 
who participated in SLS and the importance of (1) local advertising to raise community 
awareness of study recruitment; (2) site/investigator engagement, ensuring that through 
extensive training on good clinical practice, the study design and delivery was aligned with 
routine care; (3) provision of research nurse support at study sites, which was key to study 
delivery; (4) ease and convenience of study assessments; and (5) a need for improved study 
results dissemination [37]. 
Outcomes 
Owing to a forward-thinking and bold approach to the study design (including taking advice 
from independent experts), SLS incorporated outcomes of interest outside those typically 
included in traditional respiratory efficacy DBRCTs (e.g., HRU/care costs, PROs, patient exit 
interviews), which has provided valuable supporting data for the benefit of initiating FF/VI 
versus continuing UC in patients with COPD and asthma in routine practice [20‒24, 32, 33]. 
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Furthermore, allowing asymmetric treatment modifications in the study design 
necessitated a novel approach to safety evaluation: highly comprehensive safety analyses 
were conducted both by randomised treatment group and by actual treatment at the time 
of an event. 
The scientifically rigorous collection of real-world data in SLS offers major 
opportunities for future studies examining new research questions.  
Conclusions  
The real-world design aspect of SLS was unique, requiring careful planning and attention to 
the goals of maximising external validity while maintaining scientific rigour and securing 
suitable electronic processes for safety data collection. Key learnings from SLS that may help 
inform the design of future pragmatic effectiveness RCTs include (1) ensuring that the trial 
setting and operational infrastructure are aligned with routine clinical care; (2) recruiting a 
broad population of patients with characteristics as close as possible to patients seen in 
routine clinical practice, to maximise the generalisability and applicability of the trial results; 
(3) ensuring that patients and HCPs are suitably engaged in the trial, to maximise the 
chances of successful trial delivery; (4) careful study design, incorporating outcomes of 
value to patients, HCPs, policymakers and payers; and (5) using pre-planned analyses to 
address scientifically valid research hypotheses to ensure robustness of the acquired data. 
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Tables 
Table 1 Comparison of traditional efficacy DBRCTs and pragmatic effectiveness RCTs  
 Traditional efficacy DBRCTs Pragmatic effectiveness RCTs 
Patients  Strict inclusion/exclusion criteria 
 Patients with significant comorbidities and 
severe disease typically excluded 
 Highly selected (“ideal”) patient population 
 Limited relevance to patients in routine clinical 
care setting 
 Good inhaler technique mandated 
 High adherence mandated 
 Broad inclusion criteria, minimal exclusion criteria  
 Patients with comorbidities and severe disease 
included 
 Broad, heterogeneous patient population 
 Greater relevance to patients in routine clinical 
care setting 
 Variable inhaler technique 
 Variable (and frequently poor) adherence 
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Study design / 
conduct 
 Designed to test efficacy under near-ideal 
conditions (i.e., where confounding factors are 
minimised) 
 Provide data on the efficacy and safety of a 
medicine, albeit in an artificial  highly 
controlled setting 
 Typically conducted in specialised research 
clinics/hospitals 
 Randomisation (± stratification) and masking 
(e.g., double-blind, double-dummy) to limit 
bias due to systematic differences between 
treatment groups 
 Can assess experimental medicine versus a 
placebo or “gold standard” comparator 
 Designed to test effectiveness in the presence of 
real-world factors 
 Provide data on the overall treatment strategy in a 
real-world setting 
 Conducted in routine clinical practice in primary 
care; patient management reflective of usual 
clinical care 
 Randomisation (± stratification) to limit bias due 
to systematic differences between treatment 
groups; typically open-label in design 
 Usually assess experimental medicine against 
usual care or established standard-of-care 
 Treatment modifications permitted based on 
physician’s clinical opinion 
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 Treatment per protocol; generally treatment 
modifications are not permitted 
 Frequent study visits/monitoring 
 Adherence to treatment actively monitored 
and encouraged 
 Few mandatory study visits; limited disruption to 
patients normal routine  
 No monitoring or active encouragement of 
treatment adherence; patients’ health behaviours 
as normal 
Outcomes / 
data 
 Data have high internal validity, limited 
external validity 
 Endpoints often designed to enable regulatory 
approval/licensing 
 Data have high external validity 
 Often include additional endpoints of interest, 
e.g., healthcare resource utilisation, patient-
reported outcomes  
Transferability / 
generalisability 
 Treatment effect in the real world has to be 
estimated 
 Culturally accepted as most informative and 
therefore transferable, although external 
validity is weak 
 Data more generalisable to the overall disease 
population 
 Effect of healthcare systems and access to 
medicines and cultural factors may need to be 
considered 
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DBRCT double-blind randomised controlled trial, RCT randomised controlled trial 
 
 
 
 
 
 
 
 
 
46     Leather et al. ADTH-D-19-00300_revised 23Oct19 
Table 2 SLS design aspects — issues requiring greater effort/input to resolve compared to DBRCTs, based on opinion of SLS investigators and 
operational staff 
SLS design aspect Issue(s) Solution(s) 
Recruitment of GP 
investigators 
 Almost all GPs had not previously taken part 
in clinical trials 
 GPs are busy and do not have space in their 
practices or the time to conduct clinical 
studies 
 Appointed GP ambassadors who recruited 
practices and “sold” the value of the study in their 
locality 
 Recruited a team of approximately 50 research 
nurses to support GP investigators 
Patient recruitment was 
initially slow in the SLS 
 No previous experience of recruiting in this 
environment 
 GPs very busy, limited time for recruitment 
 Personal contact from patient’s own GP critical for 
recruitment 
 Adopted a project management approach to 
patient recruitment and consent, local advertising 
and pharmacy approaches to patients 
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Medicines supply and GCP 
management, pharmacy 
involvement 
 Pharmacies are usually in competition for 
business 
 Few pharmacists had prior clinical research 
experience 
 Requirement for pharmacy study-specific 
SOPs 
 Created a pharmacy steering group to oversee 
training and SOP development, endorsement of 
pharmacy chain superintendent pharmacists [34] 
Study endpoints, analysis 
and powering 
 No prior data on which to base our power 
calculations, our statisticians had not 
previously dealt with studies like this 
 Endpoints had to be of value but be measured 
with minimal interference to patient care  
 Considerable debate with the SLS Scientific 
Committee to decide on endpoints 
 Numerous reviews of statistical plans and 
endpoints — very different to a DBRCT, where our 
confidence is higher 
Randomisation and 
stratification of patients by 
asthma severity 
 Since very few baseline investigations were 
performed, it was impossible to stratify 
according to lung function or usual measures 
of disease severity 
 Novel approaches to stratification were 
developed, such as the issuing of a “dummy 
prescription” by GP at baseline assessment, which 
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allowed us to stratify according to intended 
treatment  
Electronic collection of 
pharmacy dispensing data 
 Pharmacy systems in the UK are primarily 
stock control and labelling systems, and many 
different systems are used 
 Bespoke solution created, which took an 
incredible amount of work 
Safety monitoring to GCP 
standards 
 This had not been done previously and as we 
were using EHR triggers to detect certain 
study endpoints and safety signals, we had to 
think completely differently to safety 
monitoring in a DBRCT 
 Worked with the sponsor’s pharmacovigilance 
team to build a robust safety system. 
 Had a consultant physician-led safety team (two 
physicians and four nurses) monitoring signals on 
a daily basis [19] 
Data quality and standards 
 
 Use of EHRs and effort required to ensure 
that data was of high enough standard to 
meet GCP requirements 
 Implemented a much higher than usual 
investment in data cleaning and data quality 
 The EHR needed an additional programme to 
collect relevant (and delete irrelevant) data. Level 
of quality and governance not adequate to start 
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 Sponsor’s experience from data governance 
was a need to take EHR to a higher level 
with and required an audit → fix → audit 
approach 
DBRCT double-blind randomised controlled trial, EHR electronic health record, GCP Good Clinical Practice, GP general practitioner, SLS Salford 
Lung Studies, SOP standard operating procedure, UK United Kingdom 
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Figures 
Fig. 1. Design aspects of traditional efficacy DBRCTs compared with pragmatic effectiveness 
RCTs. DBRCT double-blind randomised controlled trial, RCT randomised controlled trial 
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Fig. 2. SLS trial designs. (A) SLS COPD (B) SLS asthma. ACT Asthma Control Test, COPD 
chronic obstructive pulmonary disease, FF/VI fluticasone furoate/vilanterol, GP general 
practitioner, ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA long-acting 
muscarinic antagonist, SLS Salford Lung Study, UC usual care, Y years 
 
 
